Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences submitted copies of newspaper advertisements published on February 13, 2026 in Business Standard and Lokmat, containing its unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. On a consolidated basis, Q3 total income from operations stood at Rs 544.55 crore, down from Rs 676.23 crore in the year-ago quarter. Net profit after tax fell sharply to Rs 29.02 crore from Rs 153.48 crore, with basic EPS dropping to Rs 0.96 from Rs 4.02. For the nine-month period, consolidated net profit after tax declined to Rs 141.81 crore versus Rs 484.24 crore last year. Standalone Q3 net profit after tax was Rs 47.29 crore, down from Rs 153.86 crore a year ago.
The Q3 results show a significant year-on-year decline in both revenue and profitability, with net profit dropping roughly 80% on a consolidated basis, which is likely to be viewed negatively by shareholders and could weigh on the stock in the near term.